Scientists Achieve Rapid Whole-Brain Imaging with Single Cell Resolution
|
By LabMedica International staff writers Posted on 15 Jun 2014 |

Image: Marmoset brain created using the CUBIC method (Photo courtesy of RIKEN).
An intensive effort has been made, particularly in the brain, to determine how neural activity is converted into consciousness and other complicated brain activities. A new high-throughput technology called CUBIC (clear, unobstructed brain imaging cocktails and computational analysis) appears to be a giant leap forward, as it offers unprecedented rapid whole-brain imaging at single cell resolution with a straightforward protocol to clear and make the brain sample transparent based on the use of amino-alcohols.
A key problem of systems biology is determining how phenomena at the cellular scale correlate with activity at the organism level. One example of the technologies that may provide better understanding of these phenomena is whole-brain imaging at single-cell resolution. This imaging typically involves preparing a highly transparent sample that minimizes light scattering and then imaging neurons tagged with fluorescent probes at different slices to generate a three-dimensional (3D) representation. However, limitations in current techniques prevent comprehensive study of the relationship. The project’s findings were published April 24, 2014, in the journal Cell.
In combination with light sheet fluorescence microscopy, CUBIC was evaluated for rapid imaging of a number of mammalian systems, such as mouse and primate, demonstrating its scalability for brains of different size. Moreover, it was used to acquire new spatial-temporal details of gene expression patterns in the hypothalamic circadian rhythm center. Moreover, by combining images captured from opposite directions, CUBIC enables whole brain imaging and direct comparison of brains in diverse environmental settings.
CUBIC tackles a number of obstacles compared with earlier strategies. One is the clearing and transparency protocol, which involves serially immersing fixed tissues into just two reagents for a comparatively short time. Second, CUBIC is compatible with many fluorescent probes because of low quenching, which allows for probes with longer wavelengths and lessens concern for scattering when whole brain imaging, while at the same time provides multicolor imaging. Lastly, it is highly reproducible and scalable. Whereas other approaches have achieved some of these abilities, CUBIC is the first to accomplish it all.
CUBIC provides data on earlier unattainable 3D gene expression profiles and neural networks at the systems level. Because of its rapid and high-throughput imaging, CUBIC offers an amazing opportunity to study localized effects of genomic editing. It also is expected to identify neural connections at the whole brain level. Last author Dr. Hiroki Ueda, from RIKEN (Saitama, Japan) is excited about further applications to even larger mammalian systems. “In the near future, we would like to apply CUBIC technology to whole-body imaging at single cell resolution.”
Related Links:
RIKEN
A key problem of systems biology is determining how phenomena at the cellular scale correlate with activity at the organism level. One example of the technologies that may provide better understanding of these phenomena is whole-brain imaging at single-cell resolution. This imaging typically involves preparing a highly transparent sample that minimizes light scattering and then imaging neurons tagged with fluorescent probes at different slices to generate a three-dimensional (3D) representation. However, limitations in current techniques prevent comprehensive study of the relationship. The project’s findings were published April 24, 2014, in the journal Cell.
In combination with light sheet fluorescence microscopy, CUBIC was evaluated for rapid imaging of a number of mammalian systems, such as mouse and primate, demonstrating its scalability for brains of different size. Moreover, it was used to acquire new spatial-temporal details of gene expression patterns in the hypothalamic circadian rhythm center. Moreover, by combining images captured from opposite directions, CUBIC enables whole brain imaging and direct comparison of brains in diverse environmental settings.
CUBIC tackles a number of obstacles compared with earlier strategies. One is the clearing and transparency protocol, which involves serially immersing fixed tissues into just two reagents for a comparatively short time. Second, CUBIC is compatible with many fluorescent probes because of low quenching, which allows for probes with longer wavelengths and lessens concern for scattering when whole brain imaging, while at the same time provides multicolor imaging. Lastly, it is highly reproducible and scalable. Whereas other approaches have achieved some of these abilities, CUBIC is the first to accomplish it all.
CUBIC provides data on earlier unattainable 3D gene expression profiles and neural networks at the systems level. Because of its rapid and high-throughput imaging, CUBIC offers an amazing opportunity to study localized effects of genomic editing. It also is expected to identify neural connections at the whole brain level. Last author Dr. Hiroki Ueda, from RIKEN (Saitama, Japan) is excited about further applications to even larger mammalian systems. “In the near future, we would like to apply CUBIC technology to whole-body imaging at single cell resolution.”
Related Links:
RIKEN
Latest BioResearch News
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
New Blood Test Can Help Predict Testicular Cancer Recurrence
Stage 1 testicular germ cell tumor is typically treated with surgery followed by active surveillance. Although most patients experience strong long-term outcomes, about one in four will see their cancer... Read more
New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
Alzheimer’s disease begins developing years before memory loss or other symptoms become visible. Misfolded proteins gradually accumulate in the brain, disrupting normal cellular processes.... Read more
New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
Multiple sclerosis (MS) affects nearly three million people worldwide and can cause symptoms such as numbness, visual disturbances, fatigue, and neurological disability. Diagnosing the disease can be challenging... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
Molecular Imaging to Reduce Need for Melanoma Biopsies
Melanoma is the deadliest form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Because early melanomas can closely resemble benign moles, clinicians often rely on visual... Read more
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







